Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer
暂无分享,去创建一个
P. Conti | C. Higano | B. Tombal | C. Sternberg | J. Bellmunt | O. Sartor | D. George | N. Shore | P. Sandström | K. Chandrawansa | F. Saad | K. Miller | F. Verholen | J. P. Sade | M. Smith
[1] W. Zwart,et al. Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223 , 2021, Prostate Cancer and Prostatic Diseases.
[2] F. Saad,et al. Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis. , 2021 .
[3] J. Carles,et al. Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group. , 2020, European urology oncology.
[4] K. Aben,et al. Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. , 2020, Future oncology.
[5] F. Saad,et al. A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] F. Saad,et al. Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. , 2020, Clinical genitourinary cancer.
[7] W. Zwart,et al. A prospective observational registry evaluating clinical outcomes of Radium‐223 treatment in a nonstudy population , 2019, International journal of cancer.
[8] A. Yokomizo,et al. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases , 2019, International Journal of Clinical Oncology.
[9] F. Saad,et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.
[10] E. Andrews,et al. Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States , 2019, Prostate cancer.
[11] S. Dizdarevic,et al. Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[12] F. Saad,et al. Clinical outcome with radium-223 (Ra-223) in patients (pts) previously treated with abiraterone (Abi) or enzalutamide (Enza): A retrospective study of real-world (RW) data from pts with metastatic castration-resistant prostate cancer (mCRPC). , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] S. Fanti,et al. 223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience , 2018, Tumori.
[14] A. Yokomizo,et al. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer , 2017, International Journal of Clinical Oncology.
[15] S. Fosså,et al. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. , 2017, European urology.
[16] L. Eliasson,et al. Patients' Preferences for the Treatment of Metastatic Castrate-resistant Prostate Cancer: A Discrete Choice Experiment. , 2017, Clinical therapeutics.
[17] C. Stief,et al. Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis , 2017, Radiation oncology.
[18] C. Sweeney,et al. Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer. , 2016, European urology focus.
[19] Sender Herschorn,et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis , 2016, British Medical Journal.
[20] C. Parker,et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] K. Cooney,et al. Risk of second primary tumors in men diagnosed with prostate cancer: A population‐based cohort study , 2014, Cancer.
[22] P. Hoskin,et al. Second primary cancers after radiation for prostate cancer: A systematic review of the clinical data and impact of treatment technique , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[23] I Syndikus,et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.
[24] C. Cleeland. Brief Pain Inventory Short Form , 2013 .
[25] S. Nilsson,et al. High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities? , 2006, Clinical Cancer Research.
[26] D. Brenner,et al. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery , 2000, Cancer.
[27] C. Cleeland,et al. Pain assessment: global use of the Brief Pain Inventory. , 1994, Annals of the Academy of Medicine, Singapore.
[28] J. Wardle,et al. Sleep and nighttime energy consumption in early childhood: a population‐based cohort study , 2015, Pediatric obesity.